Pfizer, Sandoz Settle Patent Suit on Mektovi Cancer Drug Copies

Pfizer Inc.’s Array BioPharma Inc. and Sandoz Inc. settled their portion of a consolidated patent-infringement suit over proposed copies of the skin-cancer drug Mektovi.

The Sandoz Group AG subsidiary’s generic versions are blocked until the six asserted patents have expired, “except as provided for in the parties’ Settlement and License Agreement,” according to a stipulation and order of dismissal approved Thursday by Judge Gregory B. Williams in the US District Court for the District of Delaware. Three of the patents expire in October 2033, two in August 2030, and one in July 2031, a court filing from the case said. ...